FibroBiologics to Present at the BIO International Convention 2024
May 07 2024 - 9:31AM
FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a
clinical-stage biotechnology company with 150+ patents issued and
pending with a focus on the development of therapeutics and
potential cures for chronic diseases using fibroblasts and
fibroblast-derived materials, today announced that Founder and
Chief Executive Officer, Pete O’Heeron, will present a corporate
update on recent business and clinical developments at the 2024 BIO
International Convention, June 3-6, 2024, in San Diego,
California. The presentation will occur on Tuesday, June 4,
2024, at 11:45 a.m. PDT in Theater 3.
"Since presenting at the BIO International
Convention last year, FibroBiologics has made tremendous progress
as a company. This will be the first year we present at the
conference as a public company after a successful direct listing in
January," said Pete O’Heeron. "We are thrilled to showcase our
latest advancements and the potential of our fibroblast-based
therapies in multiple indications. This is a pivotal time for us,
and we eagerly anticipate discussing our innovative approaches,
discoveries and proprietary cell therapies with our peers forging
new collaborations and pathways in biotech.”
To schedule a meeting at the BIO International
Convention with FibroBiologics, please submit a meeting request
through the BIO One-on-One Partnering™ platform. For more
information, please visit FibroBiologics' website or
email FibroBiologics at info@fibrobiologics.com.
About FibroBiologics
Based in Houston, FibroBiologics is a cell
therapy and regenerative medicine company developing a pipeline of
treatments and seeking potential cures for chronic diseases using
fibroblast cells and fibroblast-derived materials. FibroBiologics
holds 150+ US and internationally issued patents/patents pending
across various clinical pathways, including disc degeneration,
orthopedics, multiple sclerosis, wound healing, reversing organ
involution, and cancer. FibroBiologics represents the next
generation of medical advancement in cell therapy. For more
information, visit www.FibroBiologics.com.
General
Inquiries:info@fibrobiologics.com
Investor Relations:Nic
JohnsonRusso Partners212-845-4242fibrobiologicsIR@russopr.com
Media Contact:Liz PhillipsRusso
Partners(347) 956-7697Elizabeth.phillips@russopartnersllc.com
FibroBiologics (NASDAQ:FBLG)
Historical Stock Chart
From May 2024 to Jun 2024
FibroBiologics (NASDAQ:FBLG)
Historical Stock Chart
From Jun 2023 to Jun 2024